Association of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining

Ma,Ding; Zhou,Zhe; Yang,Bing; He,Qun; Zhang,Qian; Zhang,Xiang‑Hua

doi:10.3892/ol.2015.3556

Association of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining

Authors:
- Ding Ma
- Zhe Zhou
- Bing Yang
- Qun He
- Qian Zhang
- Xiang‑Hua Zhang
View Affiliations

Affiliations: Department of Urology, Peking University Shougang Hospital, Beijing 100144, P.R. China, Department of Urology, Peking University First Hospital, Beijing 100034, P.R. China
Published online on: July 31, 2015 https://doi.org/10.3892/ol.2015.3556
Pages: 2185-2191
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the prognostic role of metallothionein-2A (MT-2A), E-cadherin, interleukin-6 (IL-6), cyclin-E, proliferating cell nuclear antigen (PCNA) and B cell lymphoma (Bcl)‑2 in the biochemical recurrence of prostate cancer (PCa) using tissue microarray immunostaining. Tissue specimens from 128 PCa patients who underwent radical prostatectomy were processed and transferred onto tissue microarrays. The clinicopathological parameters of PCa patients were also recorded. Following immunohistochemical examination of MT‑2A, E‑cadherin, IL‑6, cyclin‑E, PCNA and Bcl‑2 expression in PCa specimens, association analysis of biomarkers expression with the biochemical recurrence of PCa was performed. The results revealed that the overall rate of biochemical recurrence was 30.5% (39/128) and the median biochemical recurrence‑free time was 19 months (range, 6‑35 months). The biochemical recurrence rates in low‑, intermediate‑ and high‑risk PCa classification were 14.8 (8/54), 38.7 (24/62) and 58.3% (7/12), respectively. Survival analysis demonstrated that a decreased biochemical recurrence‑free survival rate was noted in PCa cases with positive MT‑2A and cyclin E expression as well as those with negative E‑cadherin expression (P=0.022, 0.028 and 0.011, respectively). Subsequent multivariate Cox analysis revealed that MT‑2A [hazard ratio (HR)=2.01; 95% confidence interval (CI)=1.08‑3.15; P=0.005], E‑cadherin (HR=1.79; 95% CI=1.08‑2.21; P=0.042) and cyclin E (HR=1.92; 95% CI=1.22‑2.45; P=0.020) were independent predictors of the biochemical recurrence of PCa. In conclusion, the present study provided clinical evidence that evaluation of molecular biomarkers expression may improve clinical prognostic accuracy for the biochemical recurrence of PCa. Of note, the expression of MT-2A, cyclin E and E-cadherin may serve as independent predictors for biochemical recurrence of PCa.

View Figures

View References

1	Grönberg H: Prostate cancer epidemiology. Lancet. 361:859–864. 2003. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
3	Diamandis EP: Prostate-specific antigen: Its usefulness in clinical medicine. Trends Endocrinol Metab. 9:310–316. 1998. View Article : Google Scholar : PubMed/NCBI
4	Abdollah F, Karnes RJ, Suardi N, et al: Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. 65:554–562. 2014. View Article : Google Scholar : PubMed/NCBI
5	Saraon P, Jarvi K and Diamandis EP: Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 57:1366–1375. 2011. View Article : Google Scholar : PubMed/NCBI
6	Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC and Partin AW: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 294:433–439. 2005. View Article : Google Scholar : PubMed/NCBI
7	D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE and Wein A: Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 55:572–577. 2000. View Article : Google Scholar : PubMed/NCBI
8	Tsivian M, Sun L, Mouraviev V, Madden JF, Mayes JM, Moul JW and Polascik TJ: Changes in gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology. 74:1090–1093. 2009. View Article : Google Scholar : PubMed/NCBI
9	Budäus L, Isbarn H, Eichelberg C, Lughezzani G, Sun M, Perrotte P, Chun FK, Salomon G, Steuber T, Köllermann J, et al: Biochemical recurrence after radical prostatectomy: Multiplicative interaction between surgical margin status and pathological stage. J Urol. 184:1341–1346. 2010. View Article : Google Scholar : PubMed/NCBI
10	Miyake H, Muramaki M, Kurahashi T, et al: Expression of potential molecular markers in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol. 28:145–151. 2010. View Article : Google Scholar : PubMed/NCBI
11	Thirumoorthy N, Shyam Sunder A, Manisenthil Kumar K, Senthil Kumar M, Ganesh G and Chatterjee M: A review of metallothionein isoforms and their role in pathophysiology. World J Surg Oncol. 9:542011. View Article : Google Scholar : PubMed/NCBI
12	Theocharis SE, Margeli AP, Klijanienko JT and Kouraklis GP: Metallothionein expression in human neoplasia. Histopathology. 45:103–118. 2004. View Article : Google Scholar : PubMed/NCBI
13	Putzke AP, Ventura AP, Bailey AM, et al: Metastatic progression of prostate cancer and e-cadherin: Regulation by Zeb1 and Src family kinases. Am J Pathol. 179:400–410. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nguyen DP, Li J and Tewari AK: Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU Int. 113:986–992. 2014. View Article : Google Scholar : PubMed/NCBI
15	Balk SP and Knudsen KE: AR, the cell cycle and prostate cancer. Nucl Recept Signal. 6:e0012008.PubMed/NCBI
16	Azevedo A, Cunha V, Teixeira AL and Medeiros R: IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2:384–396. 2011. View Article : Google Scholar : PubMed/NCBI
17	Moul JW: Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol. 35:399–407. 1999. View Article : Google Scholar : PubMed/NCBI
18	Mohler JL: The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 8:1452010.PubMed/NCBI
19	Yu H, Diamandis EP, Wong PY, Nam R and Trachtenberg J: Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG/L. J Urol. 157:913–918. 1997. View Article : Google Scholar : PubMed/NCBI
20	Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP and Bubendorf L: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate. 55:20–29. 2003. View Article : Google Scholar : PubMed/NCBI
21	TsurumakiSato Y, Fukuhara H, Suzuki M, Fujimura T, Nakagawa T, Nishimatsu H, Kume H, Morikawa T, Fukayama M and Homma Y: Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. BMC Urol. 14:132014. View Article : Google Scholar : PubMed/NCBI
22	Murphy AM, Berkman DS, Desai M, Benson MC, McKiernan JM and Badani KK: The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy. BJU Int. 105:176–179. 2010. View Article : Google Scholar : PubMed/NCBI
23	Lim D, Jocelyn KM, Yip GW and Bay BH: Silencing the metallothionein-2A gene inhibits cell cycle progression from G1-to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer lett. 276:109–117. 2009. View Article : Google Scholar : PubMed/NCBI
24	Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, et al: Cyclin E overexpression and amplification in human tumours. J Pathol. 200:375–382. 2003. View Article : Google Scholar : PubMed/NCBI
25	Rao PS, Jaqqi M, Smith DJ, Hemstreet GP and Balaji KC: Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer. Biochem Biophys Res Commun. 310:1032–1038. 2003. View Article : Google Scholar : PubMed/NCBI
26	Garrett SH, Sens MA, Shukla D, Flores L, Somji S, Todd JH and Sens DA: Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT-1X in advanced prostate cancer. Prostate. 43:125–135. 2000. View Article : Google Scholar : PubMed/NCBI
27	Gumulec J, Raudenska M, Adam V, Kizek R and Masarik M: Metallothionein-immunohistochemical cancer biomarker: A meta-analysis. PLoS One. 9:e853462014. View Article : Google Scholar : PubMed/NCBI
28	Zhong WD, Liang YX, Lin SX, Li L, He HC, Bi XC, Han ZD, Dai QS, Ye YK, Chen QB, et al: Expression of CD147 is associated with prostate cancer progression. Int J Cancer. 130:300–308. 2012. View Article : Google Scholar : PubMed/NCBI
29	Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A and Balaji KC: Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol. 23:402–406. 2005. View Article : Google Scholar : PubMed/NCBI
30	Gravdal K, Halvorsen OJ, Haukaas SA and Akslen LA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI
31	Wu TT, Hsu YS, Wang JS, Lee YH and Huang JK: The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. J Urol. 170:78–81. 2003. View Article : Google Scholar : PubMed/NCBI
32	Nariculam J, Freeman A, Bott S, Munson P, Cable N, BrookmanAmissah N, Williamson M, Kirby RS, Masters J and Feneley M: Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: The expression of Bcl-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl. 11:109–118. 2009. View Article : Google Scholar : PubMed/NCBI
33	Ishiguro H, Akimoto K, Nagashima Y, Kagawa E, Sasaki T, Sano JY, Takagawa R, Fujinami K, Sasaki K, Aoki I, et al: Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence. Cancer Sci. 102:1576–1581. 2011. View Article : Google Scholar : PubMed/NCBI
34	Zhong W, Peng J, He H, Wu D, Han Z, Bi X and Dai Q: Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med. 31:E8–E15. 2008.PubMed/NCBI